Skip to Content
MilliporeSigma
Get 22% off for Pi Day through March 31.Save Now

Key Documents

View All Documentation

Skip To

B9061

Bicalutamide (CDX)

≥98% (HPLC), non-steriodal Androgen Receptor (AR) Antagonist, powder

Synonym(s):

Casodex, Cosudex, N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
10 mg

Estimated to ship onMarch 23, 2026fromMILWAUKEE

$159.00
50 mg

Estimated to ship onMarch 23, 2026fromMILWAUKEE

$624.00

About This Item

Empirical Formula (Hill Notation):
C18H14F4N2O4S
CAS Number:
90357-06-5
Molecular Weight:
430.37
UNSPSC Code:
12352200
PubChem Substance ID:
329773312
NACRES:
NA.77
MDL number:
MFCD00869971
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated, protect from light

$159.00

Estimated to ship onMarch 23, 2026Details

​
Request a Bulk Order
​
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Bicalutamide (CDX), ≥98% (HPLC), powder

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated, protect from light

solubility

DMSO: >5 mg/mL, H2O: insoluble

originator

AstraZeneca

SMILES string

CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F

InChI

1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)

InChI key

LKJPYSCBVHEWIU-UHFFFAOYSA-N

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
1071202Y0001444PHR1678
Bicalutamide (CDX) ≥98% (HPLC), powder

Sigma-Aldrich

B9061

Bicalutamide (CDX)

Bicalutamide United States Pharmacopeia (USP) Reference Standard

USP

1071202

Bicalutamide

Bicalutamide European Pharmacopoeia (EP) Reference Standard

Y0001444

Bicalutamide

Bicalutamide Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1678

Bicalutamide

form

powder

form

-

form

-

form

-

assay

≥98% (HPLC)

assay

-

assay

-

assay

-

Quality Level

100

Quality Level

-

Quality Level

-

Quality Level

300

originator

AstraZeneca

originator

-

originator

-

originator

-

storage condition

desiccated, protect from light

storage condition

-

storage condition

-

storage condition

-

solubility

H2O: insoluble, DMSO: >5 mg/mL

solubility

-

solubility

-

solubility

-

Application

Bicalutamide (CDX) has been used as an androgen receptor (AR) antagonist in prostate, bladder cancer cell lines and human fetal skeletal muscle cells. It has also been used as a supplement in RPMI 1640 for culturing androgen-independent LNCaP (LNCaP-AI) cell line.

Biochem/physiol Actions

Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) Antagonist and a pure antiandrogen.
Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) antagonist and a pure antiandrogen. It acts via balancing histone acetylation/deacetylation and recruitment of coregulators. Bicalutamide (CDX) abolishes androgen-mediated expression. For example, MMP13 upregulation in prostate cancer, PLZF (promyelocytic leukemia zinc finger protein), and GADD45γ (growth arrest and DNA damage inducible, gamma). Bicalutamide (CDX) is inhibited by non-genomic, transcription-independent stimulation of PI3K/AKT phosphorylation by androgens.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Danger

Hazard Classifications

Aquatic Chronic 1 - Carc. 2 - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000248318
0000248318
0000186806
0000186806
0000083371

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth
Zhu YP, et al.
Testing, 6(16), 14488-14488 (2015)
Benoît Boutin et al.
The Prostate, 73(10), 1090-1102 (2013-03-28)
Treatment of advanced prostate cancer (PCa) relies on pharmacological or surgical androgen deprivation. However, it is only temporarily efficient. After a few months or years, the tumor relapses despite the absence of androgenic stimulation: a state referred to as hormone-refractory
Päivi Östling et al.
Cancer research, 71(5), 1956-1967 (2011-02-24)
Androgen receptor (AR) is expressed in all stages of prostate cancer progression, including in castration-resistant tumors. Eliminating AR function continues to represent a focus of therapeutic investigation, but AR regulatory mechanisms remain poorly understood. To systematically characterize mechanisms involving microRNAs
Testosterone insulin-like effects: an in vitro study on the short-term metabolic effects of testosterone in human skeletal muscle cells
Antinozzi C, et al.
Journal of Endocrinological Investigation, 40(10), 1133-1143 (2017)
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
Martin AM, et al.
Prostate Cancer and Prostatic Diseases, 18(4), 325-325 (2015)
View All Related Papers

Articles

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

Related Content

Global Trade Item Number

SKUGTIN
B9061-10MG04061833443569
B9061-50MG04061832823928

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service